Clinical effectiveness and safety of cetirizine versus rupatadine in chronic spontaneous urticaria: A randomized, double-blind, 6-week trial

International Journal of Dermatology

Volumn 53, Issue 5, 2014, Pages 643-649

  Dakhale, Ganesh N ^a   Shinde, Abhijit T ^a   Mahatme, Mohini S ^a   Hiware, Sachin K ^a   Mishra, Dharmendra B ^a   Mukhi, Jayesh I ^a   Salve, Anoop M ^a  

^a GOVERNMENT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CETIRIZINE; CREATININE; RUPATADINE; CYPROHEPTADINE; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BODY SURFACE; CHRONIC SPONTANEOUS URTICARIA; CHRONIC URTICARIA; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONSULTATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; EOSINOPHIL COUNT; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PATIENT COMPLIANCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH IRRITATION; UREA BLOOD LEVEL; ANALOGS AND DERIVATIVES; CHRONIC DISEASE; COMPARATIVE STUDY; PROSPECTIVE STUDY; URTICARIA;

ADULT; CETIRIZINE; CHRONIC DISEASE; CYPROHEPTADINE; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; PROSPECTIVE STUDIES; URTICARIA;

EID: 84899494275     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12250     Document Type: Article

References (26)

1. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417-1426.
2. Mete N, Gulbahar O, Aydin A, et al. Low B12 levels in chronic spontaneous urticaria. J Investig Allergol Clin Immunol 2004; 14: 292-299.
3. Fernando S, Broadfoot A. Chronic urticaria: assessment and treatment. Aust Fam Physician 2010; 39: 135-139.
4. Bernstein JA. Chronic urticaria: an evolving story. Isr Med Assoc J 2005; 7: 774-777.
5. Anuradha P, Maiti R, Jyothirmai J, et al. Loratadine versus levocetirizine in chronic spontaneous urticaria: a comparative study of efficacy and safety. Indian J Pharmacol 2010; 42: 12-16.
6. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427-1443.
7. Rathi SK. Comparison of levocetirizine and cetirizine in chronic spontaneous urticaria. Indian J Dermatol 2004; 49: 130-131.
8. Gemenez-Arnau A, Pujol M, Lanosi S, et al. Rupatadine in the treatment of chronic spontaneous urticaria: a double-blind, randomized, placebo-controlled multicenter study. Allergy 2007; 62: 539-546.
9. Metz M, Maurer M. Rupatadine for the treatment of allergic rhinitis and urticaria. Expert Rev Clin Immunol 2011; 7: 15-20.
10. Keam SJ, Plosker GL. Rupatadine: a review of its use in the management of allergic disorders. Drugs 2007; 67: 457-474.
11. Kim H, Lynde C. Impact of desloratadine on symptoms and quality of life in subjects with chronic spontaneous urticaria: a multicenter, practice-based study. Arch Drug Inf 2008; 1: 63-69.
12. Yadav S, Upadhyay A, Bajaj AK. Chronic urticaria: an overview. Indian J Dermatol 2006; 51: 171-177.
13. Godse KV, Zawar V, Krupashankar D, et al. Consensus statement on the management of urticaria. Indian J Dermatol 2011; 56: 485-489.
14. Sugiura K, Hirai S, Suzuki T, et al. Evaluation of cetirizine hydrochloride-based therapeutic strategy for chronic urticaria. Nagoya J Med Sci 2008; 70: 97-106.
15. Curran MP, Scott LJ, Perry CM. Cetirizine: a review of its use in allergic disorders. Drugs 2004; 64: 523-561.
16. Patel P, Danzig M. Comparative efficacy and safety of loratadine and cetirizine in patients with chronic spontaneous urticaria. Adv Ther 1997; 14: 318-322.
17. Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic spontaneous urticaria: a randomized, double-blind, placebo-controlled study. Eur J Dermatol 2007; 17: 223-228.
18. Guerra L, Vincenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol Venereol 2006; 3: 148-152.
19. David VK, Badyal DK, Varghese A, et al. Comparative effect of newer antihistamines on psychomotor functions in Indian population. JK Science 2010; 12: 15-18.
20. Vuurman E, Theunissen E, Oers A, et al. Lack of effects between rupatadine 10 mg and placebo on actual driving performance of healthy volunteers. Hum Psychopharmacol 2007; 22: 289-297.
21. Maiti R, Jaida J, Rahman J, et al. Olopatadine hydrochloride and rupatadine fumarate in seasonal allergic rhinitis: a comparative study of efficacy and safety. J Pharmacol Pharmacother 2011; 2: 270-276.
22. Maiti R, Rahman J, Jaida J, et al. Rupatadine and levocetirizine for seasonal allergic rhinitis a comparative study of efficacy and safety. Arch Otolaryngol Head Neck Surg 2010; 136: 796-800.
23. Mion OG, Campos RA, Antila M, et al. Futura Study. Evaluation of efficacy and safety of rupatadine fumarate in the treatment of persistent allergic rhinitis. Braz J Otorhinolaryngol 2009; 75: 673-679.
24. Katiyar S, Prakash S. Pharmacological profile, efficacy and safety of rupatadine in allergic rhinitis. Prim Care Respir J 2009; 18: 57-68.
25. Marmouz F, Giralt J, Izquierdo I. Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial. J Asthma Allergy 2011; 4: 27-35.
26. Church MK, Maspero JF, Maurer M, et al. The scope of pharmacological and clinical effects of modern antihistamines, with a special focus on rupatadine. Proceedings from a satellite symposium held at the 21st World Allergy Congress, Buenos Aires, December 8, 2009. World Allergy Organ J 2010; 3(Suppl. 4): S1-S16. doi:10.1097/WOX.0b013e3181dcf50d.